Skip to main
LIVN
LIVN logo

Livanova (LIVN) Stock Forecast & Price Target

Livanova (LIVN) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

LivaNova's sales exhibited significant growth of 29%, reaching $803 million in 2024, with management forecasting further sales expansion to between $940 million and $955 million. The positive outlook is bolstered by projected market share increases for the aura6000 device, with potential sales estimates rising substantially from $30 million in 2027 to $280 million by 2029 in an optimistic scenario. Additionally, LivaNova's diversified revenue streams, with approximately half derived from the U.S. market and a strong presence in Europe, contribute to its robust financial foundation and growth potential in the medical-device sector.

Bears say

LivaNova faces a negative outlook due to projected revenue growth slowing to low-single digits, primarily driven by persistent challenges in its Neuromodulation and Cardiovascular businesses. Furthermore, the company is experiencing operating margin contraction alongside expectations for below-consensus earnings, exacerbating financial performance concerns. Notably, risks such as potential delays in FDA approval for key products and slower-than-anticipated growth in both Neuromodulation and Cardiopulmonary sectors contribute to the overall bearish sentiment regarding the stock.

Livanova (LIVN) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Livanova (LIVN) Forecast

Analysts have given Livanova (LIVN) a Buy based on their latest research and market trends.

According to 7 analysts, Livanova (LIVN) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $62.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $62.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Livanova (LIVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.